TrialNature communications2022

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.

Aditya Bardia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.